EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity

Naïm Bouazza iD, Michaela Semeraro, Gabrielle Lui, Léo Froelicher-Bournaud, Laure Choupeaux, Jean-Marc Treluyer iD, Sihem Benaboud, Joelle Terzic, Eric Hachulla, Philippe Remy, Jérôme Harambat, Alexandre Karras und 15 weitere

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Naïm Bouazza und 26 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Inserm, Pharmacologie et évaluations des thérapeutiques chez l'enfant et la femme enceinte, Paris, France. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Prednisolone, Models, Biological, Glucocorticoids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Programme Hospitalier de Recherche Clinique-PHRC 2017 (French Ministry of Health).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE) to forecast free prednisolone concentrations and its association with disease activity.

Methods

A total of 66 active SLE patients (adults and children) were included, and followed up prospectively (242 observations available). Plasma prednisolone concentrations were assessed using liquid chromatography‐mass spectrometry, and the data were analysed using Monolix software. The pharmacokinetic model was a one‐compartment open model with absorption lag time representing the delay for both absorption and metabolism from inactive (prednisone) to active form (prednisolone). This model predicted free concentrations, which were then used to calculate total concentrations based on established binding constants.

Results

Free prednisolone clearance (CLu/F) and volume of distribution (Vu/F) were scaled allometrically to body weight. The typical population estimates (95% confidence interval) were 54 (48–62) L/h/70 kg and 235 (203–274) L/70 kg, respectively. Additionally, the bioavailability parameter was found to decrease non‐linearly with the dose. Prednisolone cumulative exposure was not different between patients who responded at 3 months and those who did not.

Conclusions

Robust pharmacokinetic targets are not yet clearly defined regarding toxicity or efficacy and are warranted in order to make a valuable contribution to prednisolone therapeutic drug monitoring in the context of SLE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicPrednisoloneModels, BiologicalGlucocorticoidsHumansFemaleMaleAdultMiddle AgedChildAdolescentYoung AdultProspective StudiesBiological AvailabilitySeverity of Illness IndexFollow-Up Studies

Stichwörter der Autor:innen

disease activitypopulation pharmacokinetics

Substanzen

PrednisoloneGlucocorticoids

Autor:innen und Institutionen

  • Université Paris Cité, Inserm, Pharmacologie et évaluations des thérapeutiques chez l'enfant et la femme enceinte, Paris, France.
  • Unité de Recherche Clinique Necker Cochin, AP-HP, France.
  • CIC-1419 Inserm, Cochin-Necker, Paris, France.
  • Service de Pharmacologie Clinique, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre, France.
  • Nephrology Dialysis Transplantation Children's Unit, University Hospital Hautepierre, Strasbourg, France.
  • Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, CERAINOM, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.

ORCID-Profile: Naïm Bouazza, Jean-Marc Treluyer

Förderung

  • Programme Hospitalier de Recherche Clinique-PHRC 2017 (French Ministry of Health)

Zitieren

APA

Bouazza, N., Semeraro, M., Lui, G., Froelicher-Bournaud, L., Choupeaux, L., Treluyer, J. M., Benaboud, S., Terzic, J., Hachulla, E., Remy, P., Harambat, J., Karras, A., Rousset-Rouviere, C., Jolivot, A., Amoura, Z., Daugas, E., Hummel, A., Salomon, R., Lega, J. C., …, & Bader-Meunier, B. (2025). Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70103

Vancouver

Bouazza N, Semeraro M, Lui G, Froelicher-Bournaud L, Choupeaux L, Treluyer JM, et al. Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70103

BibTeX
@article{Bouazza2025,
  author = {Bouazza, Naïm and Semeraro, Michaela and Lui, Gabrielle and Froelicher-Bournaud, Léo and Choupeaux, Laure and Treluyer, Jean-Marc and Benaboud, Sihem and Terzic, Joelle and Hachulla, Eric and Remy, Philippe and Harambat, Jérôme and Karras, Alexandre and Rousset-Rouviere, Caroline and Jolivot, Anne and Amoura, Zahir and Daugas, Eric and Hummel, Aurélie and Salomon, Rémi and Lega, Jean-Christophe and Decramer, Stéphane and Belot, Alexandre and Gobert, Delphine and Costedoat-Chalumeau, Nathalie and Faguer, Stanislas and Melki, Isabelle and Jourde-Chiche, Noémie and Bader-Meunier, Brigitte},
  title = {Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70103}
}
Kostenlos starten →